Your browser doesn't support javascript.
loading
Elevated soluble LOX-1 predicts risk of first-time myocardial infarction.
Schiopu, Alexandru; Björkbacka, Harry; Narasimhan, Gayathri; Loong, Bi Juin; Engström, Gunnar; Melander, Olle; Orho-Melander, Marju; Nilsson, Jan.
Afiliación
  • Schiopu A; Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Björkbacka H; Department of Transitional Science, Lund University, Sweden.
  • Narasimhan G; Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Loong BJ; Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Engström G; Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Melander O; Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Orho-Melander M; Department of Clinical Sciences Malmö, Lund University, Sweden.
  • Nilsson J; Department of Clinical Sciences Malmö, Lund University, Sweden.
Ann Med ; 55(2): 2296552, 2023.
Article en En | MEDLINE | ID: mdl-38134912
ABSTRACT

BACKGROUND:

There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction.

METHODS:

The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in baseline plasma.

RESULTS:

Subjects in the highest tertile of sLOX-1 had an increased risk of myocardial infarction (hazard ratio (95% CI) 1.76 (1.40-2.21) as compared with those in the lowest tertile. The presence of cardiovascular risk factors was related to elevated sLOX-1, but the association between sLOX-1 and risk of myocardial infarction remained significant when adjusting for risk factors.

CONCLUSIONS:

In this prospective population study we found an association between elevated sLOX-1, the presence of carotid disease and the risk for first-time myocardial infarction. Taken together with previous experimental findings of a pro-atherogenic role of LOX-1, this observation supports LOX-1 inhibition as a possible target for prevention of myocardial infarction.
Activation of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) represents a possible target for treatment of the residual inflammatory risk in cardiovascular patients on guideline therapy.Having high levels of soluble LOX-1, a marker of cellular LOX-1 activation, is associated with an increased risk for development of myocardial infarction and heart failure.sLOX-1 levels correlated with major cardiovascular risk factors and biomarkers reflecting LDL oxidation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aterosclerosis / Infarto del Miocardio Límite: Humans Idioma: En Revista: Ann Med Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aterosclerosis / Infarto del Miocardio Límite: Humans Idioma: En Revista: Ann Med Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Suecia Pais de publicación: Reino Unido